Vilobelimab for COVID-19: real-time analysis

Download Image

Post

c19early.org

Vilobelimab for COVID-19

1 study with 368 patients

Serious outcome risk

Vilobelimab

Control

COVID-19 Vilobelimab studies · October 2026

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)26%

Mortality (1)26%

RCTs (1)26%

Late (1)26%

00.511.5+

← Vilobelimab
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}


Dec 31 2022	Vlaar et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(22)00297-1	Anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (PANAMO): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial
Dec 31 2022	26% lower mortality (p=0.08). RCT 368 mechanically ventilated COVID-19 patients showing lower mortality with vilobelimab.